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Abstract: The European Tobacco Products Directive (TPD) was introduced in 2016 in an effort to
decrease prevalence of smoking and increase cessation in the European Union (EU). This study
aimed to explore quitting behaviours, motivation, reasons and perceptions about quitting, as well as
predictors (reported before the TPD implementation) associated with post-TPD quit status. A cohort
study was conducted involving adult smokers from six EU countries (n = 3195). Data collection
occurred pre-(Wave 1; 2016) and post-(Wave 2; 2018) TPD implementation. Bivariate and logistic
regression analyses of weighted data were conducted. Within this cohort sample, 415 (13.0%)
respondents reported quitting at Wave 2. Predictors of quitting were moderate or high education,
fewer cigarettes smoked per day at baseline, a past quit attempt, lower level of perceived addiction,
plans for quitting and the presence of a smoking-related comorbidity. Health concerns, price of
cigarettes and being a good example for children were among the most important reasons that
predicted being a quitter at Wave 2. Our findings show that the factors influencing decisions about
quitting may be shared among European countries. European policy and the revised version of TPD
could emphasise these factors through health warnings and/or campaigns and other policies.
Keywords: quit smoking; predictors; reasons; perceptions; European policies; TPD; World Health
Organization Framework Convention on Tobacco Control (WHO FCTC)
1. Introduction
Smoking and other forms of tobacco consumption are considered the single most important
cause of preventable morbidity and premature mortality worldwide, including in the European Union
(EU) [1].
The World Health Organization Framework Convention on Tobacco Control (WHO FCTC)
highlights that increasing quit attempts and long-term cessation rates are critical to reducing the
prevalence of smoking [2]. WHO FCTC Article 14 calls upon its Parties to take effective measures
to promote cessation of tobacco use and adequate treatment for tobacco dependence. WHO FCTC
Guidelines for the implementation of Article 14 include a number of evidence-based strategies, such as
internet support, quitlines, healthcare professionals’ brief advice, behavioural counselling by trained
specialists and use of cessation medications [3].
Research and tobacco dependence treatment guidelines have highlighted the effectiveness of
evidence-based tobacco treatment delivery (behavioural counselling and pharmacotherapy) to increase
long-term abstinence from smoking [4–6], while physicians’ advice and support also play an important
role in increasing cessation rates [7,8]. Results from recent studies on the key facilitators of quitting
identified, among others, motivation to quit [9], smoking-related health concerns [10,11], concerns about
the effects of smoking to others and the money spent on tobacco products [12].
Although the proportion of smokers has declined in most EU countries since 2006, the overall
smoking prevalence has remained stable since 2014 [13]. In addition, evidence shows that few
European smokers use assistance and evidence-based cessation methods to quit [14]. Greece (37.0%),
Hungary (35.0%), Poland (30.0%), Romania (28.0%), Spain (28.0%) and Germany (25.0%) are among
the European countries with the highest prevalence of smoking [13]. In these countries, quit ratios
have either decreased or remained low even though the population of former smokers has increased in
most other European countries in recent years [15].
Efforts to decrease smoking prevalence and increase cessation in the EU also include the European
Tobacco Products Directive (TPD) on the manufacture, presentation and sale of tobacco and related
products [16]. While the TPD does not have specific provisions for tobacco dependence treatment,
many of its measures promote cessation through regulation of tobacco products (e.g., packaging,
labelling, ingredients). Although limited data are currently available on the effectiveness of the TPD,
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previous research has indicated that higher levels of tobacco control policy implementation led to
lower prevalence of smoking and higher quit ratios in Europe [15].
Identifying predictors of a successful quit attempt is valuable for tailoring strategies or policies
that would help smokers quit, prioritising those most in need of intensive treatment and maximising
the use of the healthcare resources available [17].
Within the context of the TPD that has changed the tobacco control landscape in the EU, it is
also important to understand perceptions of and reasons for quitting as well as study potential
changes in quitting behaviour among European smokers during this period. This will improve our
understanding of what might help people to quit and inform policies on tobacco control in order to
maximise their impact.
In light of the above, using longitudinal data from adult smokers from six EU countries, the purpose
of this study was to explore quitting behaviours, motivation to quit, reasons and perceptions about
quitting and predictors of smoking cessation within this context.
2. Materials and Methods
2.1. Design and Participants
The current study is part of the Horizon 2020 funded project, European Regulatory Science
on Tobacco: Policy implementation to reduce lung diseases (EUREST_PLUS) [18]. Data come from
the International Tobacco Control Policy Evaluation (ITC) Project [19] Six European Country (6E)
Survey, a cohort study using a pre vs. post-TPD implementation design in six EU member states
(MS)—Germany, Greece, Hungary, Poland, Romania and Spain. A probabilistic, stratified cluster
sampling design was used to randomly sample respondents within geographic strata that were
defined according to the Nomenclature of Territorial Units for Statistics (NUTS) regions and degree
of urbanisation (urban, intermediate, rural). Clusters, approximately the size of enumeration areas,
were randomly selected proportional to population size within strata. Households were selected within
clusters using a random walk method and up to two smokers (one male, one female, where possible)
were randomly selected within households. Interviews were conducted face-to-face using computer
assisted personal interviews (CAPI). Further details about the study methodology are provided
elsewhere [20–23].
The Wave 1 (June–September 2016) sample included 6011 adults (≥18 years) who reported
smoking cigarettes at least monthly and smoked 100 or more cigarettes in their lifetime. In Wave
2 (February–May 2018), 53% of respondents were retained at follow up (n = 3195). Demographic
differences between Waves 1 and 2 due to attrition were generally small (Supplementary Table S1).
2.2. Demographic Characteristics
Demographic characteristics examined were age (18–24, 25–39, 40–54 and≥55 years); gender (male,
female); degree of urbanisation (urban, intermediate, rural); highest level of formal education completed
(low, moderate, and high); monthly gross household income (low, moderate and high) [20,24].
2.3. Smoking Behaviours
Current smoking status was categorised as either daily smoker or non-daily smoker (less than
daily but at least once per month). In Wave 2, respondents were considered to have quit smoking if
they reported not smoking for at least 30 days at the time of follow up. Smokers were asked how many
cigarettes they smoked per day (<10; 11–20; 21–30; 31+) and whether they smoked exclusively FM
(factory-made) cigarettes, RYO (roll-your-own) tobacco or both FM and RYO. Nicotine dependence
was assessed using the Heaviness of Smoking Index (low (0–1), moderate (2–4), high (5–6)) [25]
and perceived addiction with response options “not at all addicted”, “somewhat addicted” and
“very addicted”.
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2.4. Quitting Behaviours
Attempts and intentions to quit smoking were examined with the questions, “Have you ever
tried to quit smoking?” (yes, no), “How many quit attempts have you made in the last 12 months?”
(no attempt, 1+), “Are you planning to quit smoking . . . ?” (within the next month, the next 6 months,
beyond 6 months, no plans to quit), “Have you made an attempt to quit smoking in the last 12 months?”
(yes, no) and “How much do you want to quit smoking?” (not at all, a little, somewhat, a lot).
2.5. Perceptions and Reasons for Quitting
Perceptions around smoking were assessed with the questions, “In the last 30 days how often did
you think about: the harm your smoking might be doing to you?, the harm your smoking might be
doing to other people?, the money you spend on smoking?” (never, rarely, sometimes, often, very often);
“In the last 30 days, have you stubbed out a cigarette before you finished it because you thought
about the harm of smoking?” (yes, no) and “How much do you think you would benefit from health
and other gains if you were to quit smoking permanently in the next 6 months?” (not at all, slightly,
moderately, very much, extremely).
Respondents were asked, “If you decided to give up smoking completely in the next 6 months,
how sure are you that you would succeed?” (not at all sure, slightly, moderately, very, extremely) and
“How difficult would it be for you to quit smoking if you wanted to?” (not at all, slightly, moderately,
very, extremely).
Respondents were asked about reasons for quitting: “In the past 6 months, how much have
each of the following things led you to think about quitting . . . concern for your personal health?,
concern for the effect of your cigarette smoke on non-smokers?, that society disapproves of smoking?,
the price of cigarettes?, smoking restrictions at work?, smoking restrictions at public places like
restaurants, cafes and pubs?, availability of telephone helpline/quitline/information line?, advice from
a health professional to quit?, free or lower cost, stop-smoking medication?, warning labels on cigarette
packages?, setting an example for children?, close friends and family disapprove of your smoking?,
a prevention message or campaign?, being told you had a smoking related illness?, planning to have or
expecting a child?” (not at all, somewhat, very much).
2.6. Comorbidities and Depressive Symptoms
The presence of comorbidities was assessed with the questions, “Are you currently being treated
for, or do you have a current diagnosis for, any of the following?: chronic pain?, diabetes?, cancer?,
heart disease?, chronic lung disease (COPD, emphysema or chronic bronchitis)?, asthma?, tuberculosis?”
(yes, no).
Respondents were classified as displaying depressive symptoms [26] if they responded yes to at
least one of the following three questions: “During the last 30 days, have you often been bothered by
little interest or pleasure in doing things?”, “During the last 30 days, have you often been bothered by
feeling down, depressed, or hopeless?” and “Are you currently being treated for, or do you have a
current diagnosis for depression?” (yes/no).
2.7. Statistical Analysis
Descriptive data are shown as weighted percentages and 95% confidence intervals (CI).
Bivariate analysis examined the association between quit status at Wave 2 and smoking behaviours,
quitting behaviours, cessation assistance, perceptions and reasons for quitting, comorbidities and
depressive symptoms at Wave 1 (chi square test). A logistic regression model estimated the odds
of having quit by Wave 2 as a function of the following factors measured at Wave 1: daily cigarette
consumption, number of quit attempts, perceived addiction, plans to quit, self-efficacy, comorbidities
and a positive screen for depression. This regression model controlled for country, gender, age group,
degree of urbanization, household income and education. All statistical tests and CIs accounted for
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the complex sampling design, with sampling region as strata and primary sampling unit as clusters.
All p-values reported were two-tailed. Bivariate and logistic regression analyses of weighted data was
conducted using SAS-callable SUDAAN (Version 11.0.3).
3. Results
3.1. Quitters’ Demographic Characteristics
The analytic sample consisted of 3195 adult cigarette smokers recruited at Wave 1 and successfully
followed up at Wave 2. Within this cohort sample, 415 (13.0%) respondents reported having quit
at Wave 2. Specifically, 11.5% of the male and 14.0% of the female respondents at Wave 1 had quit
smoking at Wave 2. Having quit smoking at Wave 2 was reported by 16.2% of respondents in Spain,
14.8% in Romania, 13.8% in Greece, 12.0% in Hungary, 10.2% in Poland and 8.3% in Germany. Finally,
13.8% of the residents of urban locations, 13.2% of those with moderate household income and 20.7%
of those with high education at Wave 1 were quitters at Wave 2 (Supplementary Table S1). Continuing
smokers had similar demographic characteristics as quitters.
3.2. Wave 1 Smoking Behaviours and Quitting in Wave 2
As presented in Table 1, 30.0% of non-daily smokers at Wave 1 quit by Wave 2 compared to 11.5%
of daily smokers (p < 0.001). Quit rates were higher among FM smokers compared to those using RYO
or both (p = 0.004) and among those smoking <10 cigarettes per day at Wave 1 (p < 0.001). Among those
with low HSI and those who did not perceive themselves as addicted at Wave 1, 17.5% and 21.2% quit
smoking by Wave 2, respectively (p < 0.001). In addition, 14.2% of the quitters had tried to quit in
the past and 20.1% had done so within the previous year compared to 10.4% (p = 0.005) and 10.9%
(p < 0.001) among non-quitters, respectively. Among those who intended to quit within the next month
and desired a lot to quit at Wave 1, 26.9% and 18.4%, respectively, succeeded by Wave 2.
Table 1. Smoking behaviour and doctors visit characteristics at Wave 1 among smokers who quit by
Wave 2 (2018) (n = 3195) of EUREST-PLUS ITC 6 European Country Survey.





Daily smoker (369/3020) 11.5 (9.9, 13.3)
<0.001Non-daily smoker (46/175) 31.0 (21.9, 41.2)
Smokes FM/RYO *
FM only (330/2373) 13.9 (11.9, 16.2)
0.004RYO only (59/535) 10.3 (7.8, 13.5)
Both (26/287) 7.2 (4.2, 11.5)
Cigarettes/day
<10 (219/1154) 20.2 (17.0, 23.7)
<0.001
11–20 (168/1576) 10.1 (8.3, 12.1)
21–30 (16/297) 3.5 (1.7, 6.3)
31+ (12/163) 5.3 (2.3, 10.3)
Heaviness of Smoking Index
Low (0–1) (125/703) 17.5 (14.0, 21.5)
<0.001Moderate (2–4) (229/2035) 10.6 (9.0, 12.5)
High (5–6) (15/272) 4.1 (2.0, 7.1)
Perceived addiction
Not at all (90/410) 21.2 (16.7, 26.5)
<0.001Somewhat (210/1491) 14.4 (12.1, 17.1)
Very addicted (115/1287) 7.4 (5.8, 9.3)
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Table 1. Cont.




Ever tried to quit smoking
Never tried to quit (143/1344) 10.4 (8.4, 12.9)
0.005Ever tried to quit (272/1851) 14.2 (12.2, 16.5)
Intentions to quit
In the next month (42/142) 26.9 (18.2, 37.1)
<0.001
In the next 6 months (50/268) 16.8 (11.5, 23.3)
Beyond 6 months (131/990) 14.0 (11.4, 16.9)
No plans to quit (192/1795) 10.2 (8.3, 12.5)
Desire to quit
Not planning to quit (192/1795) 10.2 (8.3, 12.5)
<0.001
A little (32/300) 11.3 (6.8, 17.2)
Somewhat (85/573) 15.7 (12.3, 19.7)
A lot (105/522) 18.4 (14.5, 22.9)
Attempts to quit in past year
Did not try (291/2586) 10.9 (9.2, 12.8)
<0.001Tried (124/609) 20.1 (16.2, 24.7)
* FM = factory-made cigarettes; RYO = roll-your-own tobacco. ** Chi square test. Bold = p < 0.05.
3.3. Wave 1 Perceptions about Smoking and Quitting in Wave 2
Table 2 presents respondents’ perceptions about smoking by smoking status at Wave 2.
Both quitters and continuing smokers reported thinking about the harm of smoking to themselves
sometimes (32.0% vs. 30.7%) or often (20.9% vs. 19.3%), about the harm of smoking to others
sometimes (29.8% vs. 28.3%) or never (24.6% vs. 25.2%) and about money spent on smoking sometimes
(28.2% vs. 25.1%).
Table 2. Perceptions and reasons for quitting of the cohort sample (n = 3195) of EUREST-PLUS ITC 6E




Quit Status in Wave 2
p-Value *Quitters = 415 Continuing Smokers = 2780
n % (95% CI) n % (95% CI)
Wave 1 Perceptions
Think about harm of smoking
Never 80 21.3 (16.3, 27.3) 590 21.8 (19.5, 24.4) 0.917
Rarely 75 17.7 (13.5, 22.8) 527 19.4 (17.3, 21.7)
Sometimes 127 32.0 (26.6, 37.9) 863 30.7 (28.3, 33.2)
Often 94 20.9 (16.5, 26.0) 544 19.3 (17.3, 21.4)
Very often 39 8.2 (5.2, 12.0) 249 8.8 (7.4, 10.4)
Think about harm to others
Never 92 24.6 (18.8, 31.4) 684 25.2 (22.5, 28.1) 0.965
Rarely 86 22.5 (17.8, 28.0) 584 22.2 (20.2, 24.4)
Sometimes 130 29.8 (24.9, 35.3) 814 28.3 (25.8, 31.0)
Often 72 15.9 (12.1, 20.7) 485 17.3 (15.4, 19.3)
Very often 34 7.1 (4.5, 10.6) 207 7.0 (5.7, 8.5)
Think about money spent on smoking
Never 87 23.1 (18.3, 28.8) 462 16.9 (14.6, 19.4) 0.058
Rarely 54 12.3 (9.0, 16.5) 348 13.7 (11.9, 15.8)
Sometimes 114 28.2 (23.1, 33.9) 717 25.1 (22.9, 27.5)
Often 85 19.4 (14.9, 24.9) 696 25.7 (23.5, 28.1)
Very often 74 17.0 (12.8, 22.3) 554 18.5 (16.4, 20.9)





Quit Status in Wave 2
p-Value *Quitters = 415 Continuing Smokers = 2780
n % (95% CI) n % (95% CI)
Stubbed out cigarette before finishing
Yes 70 16.2 (12.2, 21.1) 444 16.2 (13.9, 18.8) 0.982
No 342 83.8 (78.9, 87.8) 2335 83.8 (81.2, 86.1)
Wave 1 reasons for quitting
Confidence to quit
Not at all sure 90 22.4 (17.6, 28.2) 932 33.6 (31.1, 36.3) <0.001
Slightly sure 108 27.3 (22.2, 32.9) 831 30.5 (27.9, 33.2)
Moderately sure 96 24.5 (19.8, 29.8) 576 22.0 (19.9, 24.3)
Very sure 65 16.3 (12.7, 20.7) 235 8.1 (6.9, 9.4)
Extremely sure 40 9.5 (6.0, 14.2) 144 5.8 (4.6, 7.2)
Difficulty in quitting
Not at all difficult 53 14.1 (10.4, 19.0) 174 6.9 (5.6, 8.4) <0.001
Slightly difficult 99 24.6 (20.6, 29.1) 473 17.9 (16.0, 20.0)
Moderately difficult 113 27.6 (22.2, 33.7) 738 26.3 (24.0, 28.7)
Very difficult 94 22.7 (18.1, 28.1) 838 30.1 (27.7, 32.5)
Extremely difficult 53 11.0 (8.2, 14.6) 533 18.9 (16.9, 21.1)
Reasons for quitting: concern for personal health
Not at all 94 25.4 (19.7, 32.2) 701 27.1 (24.6, 29.8) 0.188
Somewhat 177 42.3 (36.4, 48.5) 1292 46.3 (43.3, 49.3)
Very much 143 32.3 (26.5, 38.7) 762 26.6 (24.2, 29.1)
Reasons for quitting: effect on non-smokers health
Not at all 174 43.7 (37.1, 50.6) 1178 44.5 (41.5, 47.4) 0.754
Somewhat 167 39.1 (33.2, 45.3) 1142 40.0 (37.3, 42.8)
Very much 74 17.2 (13.3, 21.8) 435 15.5 (13.6, 17.7)
Reasons for quitting: society disapproves
Not at all 262 67.3 (61.0, 73.0) 1889 70.1 (67.0, 73.0) 0.651
Somewhat 106 24.7 (19.8, 30.5) 656 23.1 (20.6, 25.7)
Very much 38 7.9 (5.0, 11.9) 186 6.9 (5.7, 8.2)
Reasons for quitting: price of cigarettes
Not at all 115 29.7 (23.6, 36.7) 781 30.3 (27.6, 33.2) 0.976
Somewhat 153 37.7 (31.7, 44.1) 1045 37.6 (34.9, 40.3)
Very much 147 32.6 (27.1, 38.7) 935 32.1 (29.2, 35.0)
Reasons for quitting: restrictions at work
Not at all 277 67.6 (61.1, 73.6) 1892 69.8 (66.7, 72.7) 0.779
Somewhat 93 23.5 (18.3, 29.7) 598 21.6 (19.3, 24.2)
Very much 40 8.8 (5.7, 13.0) 211 8.6 (7.1, 10.3)
Reasons for quitting: restrictions in public places
Not at all 265 64.8 (58.2, 70.8) 1819 66.1 (62.7, 69.3) 0.727
Somewhat 107 26.7 (21.4, 32.8) 699 24.6 (21.8, 27.6)
Very much 41 8.5 (5.4, 12.5) 238 9.4 (7.8, 11.2)
Reasons for quitting: telephone helpline available
Not at all 319 80.5 (74.8, 85.2) 2194 80.5 (77.7, 83.1) 0.998
Somewhat 68 15.2 (11.1, 20.6) 408 15.2 (13.0, 17.7)
Very much 19 4.2 (2.0, 7.7) 117 4.3 (3.3, 5.5)
Reasons for quitting: advice from health professional
Not at all 230 59.1 (52.6, 65.2) 1694 62.7 (59.6, 65.6) 0.253
Somewhat 132 30.9 (25.6, 36.8) 734 26.5 (24.0, 29.0)
Very much 48 10.0 (6.6, 14.3) 310 10.9 (9.4, 12.6)
Reasons for quitting: affordable stop-smoking medications
Not at all 297 78.0 (72.7, 82.5) 1895 71.6 (68.7, 74.4) 0.033
Somewhat 60 13.1 (9.8, 17.2) 460 18.3 (16.0, 20.9)
Very much 38 8.9 (6.0, 12.8) 285 10.0 (8.6, 11.6)





Quit Status in Wave 2
p-Value *Quitters = 415 Continuing Smokers = 2780
n % (95% CI) n % (95% CI)
Reasons for quitting: labels on cigarette packages
Not at all 265 67.5 (61.0, 73.4) 1926 70.3 (67.2, 73.3) 0.348
Somewhat 106 23.8 (19.0, 29.4) 648 23.6 (20.9, 26.5)
Very much 42 8.7 (5.6, 12.7) 174 6.1 (4.9, 7.6)
Reasons for quitting: example for children
Not at all 171 42.6 (36.1, 49.4) 1150 43.5 (40.4, 46.6) 0.710
Somewhat 126 31.3 (25.7, 37.5) 913 32.7 (30.0, 35.6)
Very much 116 26.1 (20.9, 32.0) 660 23.8 (21.5, 26.3)
Reasons for quitting: friends and family disapprove
Not at all 228 59.0 (52.4, 65.3) 1710 62.6 (59.4, 65.6) 0.505
Somewhat 130 29.3 (23.6, 35.6) 757 27.1 (24.6, 29.7)
Very much 56 11.7 (8.9, 15.4) 273 10.4 (8.9, 12.1)
Reasons for quitting: prevention message campaign
Not at all 296 75.2 (69.2, 80.4) 2044 74.4 (71.3, 77.2) 0.873
Somewhat 90 19.8 (15.1, 25.6) 535 20.0 (17.6, 22.7)
Very much 27 5.0 (3.1, 7.6) 153 5.6 (4.4, 7.1)
Reasons for quitting: have smoking related illness
Not at all 221 54.4 (47.7, 60.9) 1499 56.8 (53.6, 60.0) 0.677
Somewhat 97 23.2 (18.3, 28.9) 650 22.9 (20.4, 25.5)
Very much 96 22.5 (18.1, 27.6) 569 20.3 (18.0, 22.8)
Reasons for quitting: planning to have a child
Not at all 277 67.0 (61.1, 72.5) 1911 71.1 (68.2, 73.9) 0.334
Somewhat 73 17.7 (13.5, 22.9) 418 16.7 (14.4, 19.2)
Very much 58 15.2 (11.4, 20.2) 324 12.2 (10.5, 14.2)
How much benefit if you quit smoking
Not at all 29 8.3 (5.1, 12.8) 272 10.6 (9.0, 12.6) 0.535
Slightly 73 17.4 (13.3, 22.5) 515 19.3 (17.2, 21.7)
Moderately 120 30.9 (25.0, 37.5) 857 31.3 (28.7, 33.9)
Very much 135 30.4 (24.9, 36.5) 782 28.4 (25.8, 31.2)
Extremely 47 13.0 (8.9, 18.1) 285 10.3 (8.6, 12.4)
* Chi square test. Bold = p < 0.05. Wave 1 Reasons for Quitting and Status in Wave 2.
Table 2 also depicts reasons for quitting at Wave 1 by smoking status at Wave 2. A greater
percentage of those who had quit smoking by Wave 2 reported being very/extremely sure that they
could quit at Wave 1 compared to continuing smokers (25.8% vs. 13.9%, respectively; p < 0.001).
Continuing smokers had also perceived quitting as something very/extremely difficult at Wave 1
compared to quitters (49.0% vs. 33.7%, p < 0.001).
Concerns for personal health, price of cigarettes, being a good example for children and having
a smoking related illness are among the reasons which were considered as the most important
for quitting at Wave 1, with little difference according to quit status at Wave 2. Reasons such as
the effect on non-smokers’ health, advice from a healthcare professional and friends and family’s
disapproval were considered as somewhat important reasons for quitting for almost a quarter of
respondents. However, reasons such as societal disapproval, restrictions at work and at public
places, helpline availability, affordability of stop-smoking medications, labels on cigarette packages,
prevention messages/campaigns and plans to have a child were considered not at all important.
Finally, only around one in ten respondents had indicated that they would not benefit at all if they quit
smoking, with no statistically significant difference when contrasted with quit status at Wave 2.
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3.4. Factors Associated with Being a Quitter during Wave 2
Table 3 presents the Wave 1 factors associated with having quit smoking by Wave 2. Living in
Greece (odds ratio (OR) 2.35; 95% CI 1.23–4.48), Hungary (OR 2.16; 95% CI 1.12–4.17) or Spain (OR 2.41;
95% CI 1.29–4.49) was associated with higher odds of quitting smoking during Wave 2 compared to
living in Germany. Respondents with moderate (OR 1.46; 95% CI 1.05–2.03) or high education (OR 2.16;
95% CI 1.42–3.29) were more likely to be quitters during Wave 2 than those with low education.
Daily cigarette consumption (11–20 cigarettes/day vs. ≤10 cigarettes/day: OR 0.64; 95% CI 0.47–0.86;
21+ cigarettes/day vs. ≤10 cigarettes/day: OR 0.30; 95% CI 0.18–0.50) was negatively associated with
quitting smoking during Wave 2 while at least one past quit attempt was positively associated with
being a quitter (OR 1.58; 95% CI 1.15–2.18). Lower level of perceived addiction (OR 2.04; 95% CI
1.34–3.11) as well as making plans for quitting within the next month (OR 1.90; 95% CI 1.13–3.20) were
also associated with higher odds of being a quitter in Wave 2. Finally, the presence of a smoking related
comorbidity predicted quitting (OR 1.59; 95% CI 1.07–2.35).
Table 3. Wave 1 factors associated with being a quitter at Wave 2 of the cohort sample (n = 3100) of
EUREST-PLUS ITC 6E Surveys.
Quitter at Wave 2
Effect OR 95% CI p-Value
Country
Germany 1.00
Greece 2.35 (1.23, 4.48) 0.010
Hungary 2.16 (1.12, 4.17) 0.021
Poland 1.29 (0.69, 2.44) 0.427
Romania 1.89 (0.99, 3.60) 0.055
Spain 2.41 (1.29, 4.49) 0.006
Gender
Male 1.00
Female 1.08 (0.86, 1.37) 0.491
Age group
18–24 1.00
25–39 0.89 (0.54, 1.45) 0.642
40–54 1.03 (0.61, 1.75) 0.901
55+ 1.11 (0.67, 1.82) 0.683
Area of living
Urban 1.00
Intermediate 0.89 (0.63, 1.26) 0.512
Rural 0.98 (0.62, 1.55) 0.925
Household income
Low 1.00
Moderate 1.19 (0.80, 1.78) 0.381
High 1.06 (0.65, 1.72) 0.822
Not reported 1.06 (0.64,1.75) 0.817
Level of education
Low 1.00
Moderate 1.46 (1.05, 2.03) 0.024
High 2.16 (1.42, 3.29) <0.001
Cigarettes per day
≤10 1.00
11–20 0.64 (0.47, 0.86) 0.003
21+ 0.30 (0.18, 0.50) <0.001
Number of quit attempts
No attempts to quit 1.00
At least one attempt 1.58 (1.15, 2.18) 0.005
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Table 3. Cont.
Quitter at Wave 2
Effect OR 95% CI p-Value
Perceived addiction level
Very addicted 1.00
Somewhat addicted 1.63 (1.18, 2.25) 0.003
Not at all 2.04 (1.34, 3.11) 0.001
Plans to quit
No plans to quit 1.00
Sometime in the future 1.28 (0.94, 1.72) 0.111
In the next month 1.90 (1.13, 3.20) 0.016
Self-efficacy
Not at all/slightly/moderately sure 1.00
Very/extremely sure can quit 1.36 (0.99, 1.87) 0.058
Comorbidities *
No 1.00
Yes 1.59 (1.07, 2.35) 0.021
Positive screen for depression
No 1.00
Yes 0.88 (0.63, 1.23) 0.455
* Comorbidities = Are you currently being treated for or do you have a current diagnosis for any of the following?
(chronic pain, diabetes, cancer, heart disease, chronic lung disease (COPD, emphysema or chronic bronchitis),
asthma, tuberculosis). Bold = p < 0.05.
4. Discussion
This is the first cohort study of adult smokers from multiple EU countries exploring quitting
behaviours, motivation to quit, reasons and perceptions about quitting and implemented policies as
well as factors (reported before TPD implementation) associated with post-TPD quit status. Moderate or
high education, consumption of <10 cigarettes per day, lower perceived addiction, at least one past
quit attempt, planning to quit and the presence of a smoking related comorbidity were identified
as predictors of being a quitter at Wave 2. Among reasons to quit smoking, policy aspects such
as restrictions at work, restrictions at public places, labels on cigarette packages and prevention
messages/campaigns as well as helpline availability and affordability of stop-smoking medications
were generally not considered as important. However, perceived harm of smoking to their health
or others, being a good example for children, having a smoking related illness and money spent on
smoking were reported as important factors for quitting.
Consistent with our findings, previous studies have shown that the level of confidence in
succeeding to quit is an important factor, also indicative of the success [27,28]. Quitters at Wave 2 also
planned to quit at Wave 1, although levels of desire to quit were low. The existing evidence supports
the role of motivation and desire in smoking cessation. However, these factors may be predictors of
attempting to quit but not of maintaining abstinence [29–32]. This indicates that motivation may be
important as a first step in the quit attempt process, but other factors could contribute to quit success.
How different aspects of the motivational system influence behaviour and maintenance should be
investigated in future research. Healthcare professionals’ support in boosting patients’ confidence in
successful quitting could be incorporated into clinical practice along with information on the efficacy
of pharmacotherapy and behavioural advice and enhance smokers’ chances of succeeding.
Our analysis also showed that higher education and household income are associated with
quitting, which aligns with previous research [33–35]. In addition, our findings concerning lighter
smoking and low levels of perceived addiction among those who quit [36–38] as well as the presence
of a disease [10,27,39] or health concerns about smoking [10,40,41] are consistent with the literature.
Others have found that suffering from a chronic disease or multiple comorbidities caused or worsened
by smoking do not always lead to cessation [42], which was true for some of our study’s respondents.
This may be explained by the fact that a successful attempt is associated with the level of nicotine
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dependence [43], which is often higher in smokers with chronic diseases [44,45] and with the intensity
of the medical support for smoking cessation provided [45].
Money spent on smoking was generally reported as an important reason for quitting, which again
highlights that price increases and taxes on tobacco products are very effective tobacco control
measures [46,47]. This might partly explain why somewhat more FM cigarette smokers quit between
Waves 1 and 2 compared to RYO and users of both. Recent increases in FM cigarette prices in Europe
have been associated with increased use of RYO, which is a cheaper form of tobacco [48–50].
Helpline availability and affordable stop-smoking medications were also not perceived as
important reasons for quitting. These are both effective strategies to support cessation but smokers
may be unaware of the effectiveness of smoking cessation treatment, underestimate their benefits [51]
or hesitate to use such services, as in many European countries, they are not reimbursed [52,53]. As a
result, use of evidence-based smoking cessation treatment and cessation aids in general is suboptimal
in Europe [13,54–56]. Increased funding for smoking cessation services and aids especially for high
risk populations (e.g., those with chronic diseases, severe mental illness, addiction HIV, Tuberculosis,
as well as pregnant women) and building on the capacity of healthcare professionals to provide tobacco
treatment services, (e.g., by offering hands-on training or digital training [57,58]) could improve the
smoking cessation landscape in Europe.
While not reported as key factors for quitting among the respondents in our study, there is
clear evidence that tobacco control policies, such as smoking restrictions at work or in public places
and warning labels on cigarette packages, contribute to smoking cessation and reduce smoking
prevalence [10,14,47]. Romania, Poland, Spain and Germany scored low or dropped on the Tobacco
Control Scale ranking since 2016 [59], while the TPD had not been fully implemented in all EU countries
by 2016, [60] when we conducted Wave 1 data collection. For example, only Hungary, Romania and
Spain had pictorial warnings on the back side of the packages and the implementation of smoke-free
legislation was poor in Greece, Poland and Germany [61]. Thus, the perceptions regarding smoking
restrictions at work or in public places may simply reflect relatively poor implementation at the time of
data collection in the countries assessed. Such differences between countries may partly explain the
variation in the proportion of smokers who reported quitting between Wave 1 and Wave 2. Greece,
for instance, implemented new tobacco control measures during the study period, improving its
position in the Tobacco Control Scale, whereas Poland dropped from the 15th to the 23rd place in the
same scale from 2016 to 2019 [59,61].
Overall, our findings regarding the reasons and predictors of quitting in Europe such as concerns
for personal health [10,62], price of cigarettes, smoking related illness, advice from a healthcare
professional, family disapproval, [10], being a good example for their children [63] and the effects
of smoking on others [11] are aligned with previous European studies. This shows that reasons
influencing decisions about quitting may be shared among European countries. European policy and
the revised version of TPD could emphasise the factors related to the health risks of smoking and
benefits of smoking cessation for oneself and others which seem to influence smokers decisions—for
instance, through health warnings and/or campaigns and other policies along with other characteristics
such as flavours, which have been found to influence smoking and cessation characteristics of the
users [64].
Study Strengths and Limitations
Although results regarding quitting and cessation behaviours from both waves of the
EUREST-PLUS Europe Surveys have been published [52,64–66], this study is the first to present
cohort data on predictors, motivation, reasons and perceptions for quitting. In addition, this study
examined an extensive number of measures and used validated tools. However, the comparably high
rate of smokers who were lost to follow up (45%) is an important limitation as differential attrition may
have introduced bias. While there were some slight differences between retained vs. lost respondents,
these differences were generally small. For instance, given that we did not find significant differences
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in intentions to quit smoking at Wave 1 (retained vs. lost respondents), associations with successful
cessation by Wave 2 might not be biased [67]. Additionally, our analysis was based on self-reported data,
which may be subject to information bias (e.g., social desirability bias). We assessed multiple variables
and thus conducted multiple comparisons. Although this carries the risk of finding statistically
significant differences by chance, most of the differences detected were significant at the 0.001 level,
which increases our confidence in the findings. Perceptions, reasons and motivation may also change
over time. Given the fact that we assessed Wave 1 in 2016, some respondents may have lost or found
motivation, perceptions and reasons to quit may have changed, with the implementation of TPD
measures possibly having contributed to this change. In addition, there may be differences between
countries in how people respond to questions about perceptions and motivation. Finally, quitting was
self-reported and defined as 30-day abstinence; we cannot verify that respondents remained abstinent
from smoking.
5. Conclusions
This study is the first to present results from the largest cross-national cohort sample of smokers
in Europe, examining the predictors of quitting, motivation, reasons and perceptions about quitting
among smokers from multiple EU MS, from 2016 to 2018. Perceptions of the personal and social impact
of smoking were considered more important than typical tobacco control policies at the time of the
study when the European landscape of tobacco control policies was changing. Although perceptions
do not necessarily reflect the actual effectiveness of various policies, these findings can inform future
tobacco control policies in Europe—for example, when designing warning labels or public campaigns.
They can also be incorporated into the revision of the TPD to enhance and strengthen existing policies
that appeal to smokers’ concerns and motivations to quit.
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